

γ - and δ -Lactams from the Leaves of *Clausena lansium*

De-Yang Shen,^{†,#} Thi Ngan Nguyen,^{‡,#} Shwu-Jen Wu,[§] Young-Ji Shiao,[⊥] Hsin-Yi Hung,[¶] Ping-Chung Kuo,[▽]
Daih-Huang Kuo,[○] Tran Dinh Thang,^{‡,*} and Tian-Shung Wu,^{¶,○,*}

[†] Department of Chemistry and [¶] School of Pharmacy, National Cheng Kung University, Tainan 70101, Taiwan

[‡] Department of Chemistry, Vinh University, Vinh City, Vietnam

[§] Department of Medical Laboratory Science and Biotechnology, Chung Hwa University of Medical Technology, Tainan 71703, Taiwan

[⊥] Division of Basic Chinese Medicine, National Research Institute of Chinese Medicine, Taipei 112, Taiwan

[▽] Department of Biotechnology, National Formosa University, Yunlin 63201, Taiwan

[○] Department of Pharmacy and Graduate Institute of Pharmaceutical Technology, Tajen University, Pingtung 90741, Taiwan


Table of Content

S 1 ^1H NMR (400 MH, CDCl_3) spectrum of the new compound 1	6
S 2 ^{13}C NMR (100 MH, CDCl_3) spectrum of the new compound 1	7
S 3 COSY spectrum of the new compound 1	8
S 4 NOESY spectrum of the new compound 1	9
S 5 HSQC spectrum of the new compound 1	10
S 6 HMBC spectrum of the new compound 1	11
S 7 CD spectrum of the new compound 1	12
S 8 ^1H NMR (400 MHz, CDCl_3) spectrum of the new compound 2	13
S 9 ^{13}C NMR (100 MHz, CDCl_3) spectrum of the new compound 2	14
S 10 COSY spectrum of the new compound 2	15
S 11 NOESY spectrum of the new compound 2	17
S 12 HSQC spectrum of the new compound 2	18
S 13 HMBC spectrum of the new compound 2	19
S 14 CD spectrum of the new compound 2	20
S 15 ^1H NMR (400 MHz, CDCl_3) spectrum of the new compound 3	21
S 16 ^{13}C NMR (100 MHz, CDCl_3) spectrum of the new compound 3	22
S 17 COSY spectrum of the new compound 3	23
S 18 NOESY spectrum of the new compound 3	24
S 19 HSQC spectrum of the new compound 3	25
S 20 HMBC spectrum of the new compound 3	26
S 21 CD spectrum of the new compound 3	27
S 22 ^1H NMR (400 MHz, CDCl_3) spectrum of the new compound 4	28
S 23 ^{13}C NMR (100 MHz, CDCl_3) spectrum of the new compound 4	29
S 24 COSY spectrum of the new compound 4	30
S 25 NOESY spectrum of the new compound 4	31
S 26 HSQC spectrum of the new compound 4	32
S 27 HMBC spectrum of the new compound 4	33
S 28 CD spectrum of the new compound 4	34
S 29 ^1H NMR (400 MHz, CDCl_3) spectrum of the new compound 5	35
S 30 ^{13}C NMR (100 MHz, CDCl_3) spectrum of the new compound 5	36
S 31 COSY spectrum of the new compound 5	37
S 32 NOESY spectrum of the new compound 5	38
S 33 HSQC spectrum of the new compound 5	39
S 34 HMBC spectrum of the new compound 5	40
S 35 CD spectrum of the new compound 5	41
S 36 ^1H NMR (400 MHz, CDCl_3) spectrum of the new compound 6	42
S 37 ^{13}C NMR (100 MHz, CDCl_3) spectrum of the new compound 6	43
S 38 COSY spectrum of the new compound 6	44
S 39 NOESY spectrum of the new compound 6	45


S 40 HSQC spectrum of the new compound 6	46
S 41 HMBC spectrum of the new compound 6	47
S 42 CD spectrum of the new compound 6	48
S 43 ^1H NMR (400 MHz, CD ₃ OD) spectrum of the new compound 7	49
S 44 ^{13}C NMR (100 MHz, CD ₃ OD) spectrum of the new compound 7	50
S 45 COSY spectrum of the new compound 7	51
S 46 NOESY spectrum of the new compound 7	52
S 47 HSQC spectrum of the new compound 7	53
S 48 HMBC spectrum of the new compound 7	54
S 49 CD spectrum of the new compound 7	55
S 50 ^1H NMR (400 MHz, CDCl ₃) spectrum of the compound 8	56
S 51 ^{13}C NMR (100 MHz, CDCl ₃) spectrum of the compound 8	57
S 52 COSY spectrum of the compound 8	58
S 53 NOESY spectrum of the compound 8	59
S 54 HSQC spectrum of the compound 8	60
S 55 HMBC spectrum of the compound 8	61
S 56 CD spectrum of the compound 8	62
S 57 X-ray structure of compound 8	63
S 58 ^1H NMR (400 MHz, CDCl ₃) spectrum of the compound 9	64
S 59 ^{13}C NMR (100 MHz, CDCl ₃) spectrum of the compound 9	65
S 60 COSY spectrum of the compound 9	66
S 61 NOESY spectrum of the compound 9	67
S 62 HSQC spectrum of the compound 9	68
S 63 HMBC spectrum of the compound 9	69
S 64 CD spectrum of the compound 9	70
S 65 ^1H NMR (400 MHz, CDCl ₃) spectrum of the compound 10	71
S 66 ^{13}C NMR (100 MHz, CDCl ₃) spectrum of the compound 10	72
S 67 COSY spectrum of the compound 10	73
S 68 NOESY spectrum of the compound 10	74
S 69 HSQC spectrum of the compound 10	75
S 70 HMBC spectrum of the compound 10	76
S 71 CD spectrum of the compound 10	77
S 72 ^1H NMR (400 MHz, CD ₃ OD) spectrum of the compound 11	78
S 73 ^{13}C NMR (100 MHz, CD ₃ OD) spectrum of the compound 11	79
S 74 COSY spectrum of the compound 11	80
S 75 NOESY spectrum of the compound 11	81
S 76 HSQC spectrum of the compound 11	82
S 77 HMBC spectrum of the compound 11	83
S 78 CD spectrum of the compound 11	84
S 79 X-ray structure of compound 11	85
S 80 ^1H NMR (400 MHz, CDCl ₃) spectrum of the compound 12	86
S 81 ^{13}C NMR (100 MHz, CDCl ₃) spectrum of the compound 12	87

S 82 COSY spectrum of the compound 12	88
S 83 NOESY spectrum of the compound 12	89
S 84 HSQC spectrum of the compound 12	90
S 85 HMBC spectrum of the compound 12	91
S 86 CD spectrum of the compound 12	92
S 87 X-ray structure of compound 12	93
S 88 ^1H NMR (400 MHz, CDCl_3) spectrum of the compound 13	94
S 89 ^{13}C NMR (100 MHz, CDCl_3) spectrum of the compound 13	95
S 90 COSY spectrum of the compound 13	96
S 91 NOESY spectrum of the compound 13	97
S 92 HSQC spectrum of the compound 13	98
S 93 HMBC spectrum of the compound 13	99
S 94 CD spectrum of the compound 13	100
S 95 CD spectrum of the compound 14	101
S 96 X-ray structure of compound 14	102
S 97 Chiral HPLC of compound 1	103
S 98 Chiral HPLC of compound 11	104
S 99 Neuroprotective Assay.....	105
S 100 Neurotoxicity Assay	105
S 101 Compound 2 prevented cell death of cortical neurons induced by $\text{A}\beta$ -(25–35).....	106


S 1 ^1H NMR (400 MHz, CDCl_3) spectrum of the new compound **1**.




S 2 ^{13}C NMR (100 MHz, CDCl_3) spectrum of the new compound **1**.




S 3 COSY spectrum of the new compound **1**.




S 4 NOESY spectrum of the new compound **1**.




S 5 HSQC spectrum of the new compound **1**.




S 6 HMBC spectrum of the new compound **1**.




S 7 CD spectrum of the new compound **1**.




S 8 ^1H NMR (400 MHz, CDCl_3) spectrum of the new compound **2**.




S 9 ^{13}C NMR (100 MHz, CDCl_3) spectrum of the new compound 2.




S 10 COSY spectrum of the new compound 2.




S 11 NOESY spectrum of the new compound **2**.




S 12 HSQC spectrum of the new compound **2**.




S 13 HMBC spectrum of the new compound 2.




S 14 CD spectrum of the new compound **2**.




S 15 ^1H NMR (400 MHz, CDCl_3) spectrum of the new compound **3**.




S 16 ^{13}C NMR (100 MHz, CDCl_3) spectrum of the new compound 3.




S 17 COSY spectrum of the new compound 3.




S 18 NOESY spectrum of the new compound **3**.




S 19 HSQC spectrum of the new compound 3.




S 20 HMBC spectrum of the new compound 3.




S 21 CD spectrum of the new compound **3**.




S 22 ^1H NMR (400 MHz, CDCl_3) spectrum of the new compound **4**.




S 23 ^{13}C NMR (100 MHz, CDCl_3) spectrum of the new compound 4.




S 24 COSY spectrum of the new compound **4**.




S 25 NOESY spectrum of the new compound **4**.




S 26 HSQC spectrum of the new compound 4.




S 27 HMBC spectrum of the new compound 4.




S 28 CD spectrum of the new compound **4**.




S 29 ^1H NMR (400 MHz, CDCl_3) spectrum of the new compound 5.




S 30 ^{13}C NMR (100 MHz, CDCl_3) spectrum of the new compound 5.




S 31 COSY spectrum of the new compound **5**.




S 32 NOESY spectrum of the new compound **5**.




S 33 HSQC spectrum of the new compound 5.




S 34 HMBC spectrum of the new compound 5.




S 35 CD spectrum of the new compound **5**.




S 36 ^1H NMR (400 MHz, CDCl_3) spectrum of the new compound **6**.




S 37 ^{13}C NMR (100 MHz, CDCl_3) spectrum of the new compound **6**.




S 38 COSY spectrum of the new compound **6**.




S 39 NOESY spectrum of the new compound **6**.




S 40 HSQC spectrum of the new compound **6**.




S 41 HMBC spectrum of the new compound **6**.




S 42 CD spectrum of the new compound **6**.




S 43 ^1H NMR (400 MHz, CD_3OD) spectrum of the new compound 7.




S 44 ^{13}C NMR (100 MHz, CD_3OD) spectrum of the new compound 7.




S 45 COSY spectrum of the new compound **7**.




S 46 NOESY spectrum of the new compound 7.




S 47 HSQC spectrum of the new compound 7.




S 48 HMBC spectrum of the new compound 7.




S 49 CD spectrum of the new compound 7.




S 50 ^1H NMR (400 MHz, CDCl_3) spectrum of the compound 8.




S 51 ^{13}C NMR (100 MHz, CDCl_3) spectrum of the compound **8**.




S 52 COSY spectrum of the compound **8**.




S 53 NOESY spectrum of the compound **8**.




S 54 HSQC spectrum of the compound **8**.




S 55 HMBC spectrum of the compound **8**.




S 56 CD spectrum of the compound 8.




S 57 X-ray structure of compound **8**.




S 58 ^1H NMR (400 MHz, CDCl_3) spectrum of the compound 9.




S 59 ^{13}C NMR (100 MHz, CDCl_3) spectrum of the compound **9**.




S 60 COSY spectrum of the compound **9**.




S 61 NOESY spectrum of the compound **9**.




S 62 HSQC spectrum of the compound **9**.




S 63 HMBC spectrum of the compound **9**.




S 64 CD spectrum of the compound 9.




S 65 ^1H NMR (400 MHz, CDCl_3) spectrum of the compound **10**.




S 66 ^{13}C NMR (100 MHz, CDCl_3) spectrum of the compound **10**.




S 67 COSY spectrum of the compound **10**.




S 68 NOESY spectrum of the compound **10**.




S 69 HSQC spectrum of the compound **10**.




S 70 HMBC spectrum of the compound **10**.




S 71 CD spectrum of the compound **10**.




S 72 ^1H NMR (400 MHz, CD_3OD) spectrum of the compound **11**.




S 73 ^{13}C NMR (100 MHz, CD_3OD) spectrum of the compound **11**.




S 74 COSY spectrum of the compound **11**.




S 75 NOESY spectrum of the compound **11**.




S 76 HSQC spectrum of the compound **11**.




S 77 HMBC spectrum of the compound **11**.




S 78 CD spectrum of the compound **11**.




S 79 X-ray structure of compound **11**.




S 80 ^1H NMR (400 MHz, CDCl_3) spectrum of the compound **12**.




S 81 ^{13}C NMR (100 MHz, CDCl_3) spectrum of the compound 12.




S 82 COSY spectrum of the compound **12**.




S 83 NOESY spectrum of the compound **12**.




S 84 HSQC spectrum of the compound **12**.




S 85 HMBC spectrum of the compound **12**.




S 86 CD spectrum of the compound **12**.




S 87 X-ray structure of compound **12**.




S 88 ^1H NMR (400 MHz, CDCl_3) spectrum of the compound **13**.




S 89 ^{13}C NMR (100 MHz, CDCl_3) spectrum of the compound **13**.




S 90 COSY spectrum of the compound **13**.




S 91 NOESY spectrum of the compound **13**.




S 92 HSQC spectrum of the compound **13**.




S 93 HMBC spectrum of the compound **13**.




S 94 CD spectrum of the compound 13.



S 95 CD spectrum of the compound **14**.




S 96 X-ray structure of compound 14.



S 97 Chiral HPLC of compound **1**

Detector A - 1 (214nm)			
Area	Retention Time	Area Percent	
2183232	14.750	3.29	
64136173	18.008	96.71	
Totals			100.00
66319405			




Gradient: *n*-Hexane/iso-Propanol; 90:10

Astec Cellulose DMP (150 × 4.6 mm i.d. 5 µm).

Set Wavelength: 214 nm

Flow rate: 1.0 mL/min

S 98 Chiral HPLC of compound **11**



Gradient: *n*-Hexane/iso-Propanol; 90:10

Astec Cellulose DMP (150 × 4.6 mm i.d. 5 µm).

Set Wavelength: 214 nm

Flow rate: 1.0 mL/min

S 99 Neuroprotective Assay


Primary cultures of neonatal cortical neurons were prepared from the cerebral cortex of Harlan Sprague-Dawley rat pups at postnatal day 1.²³ Briefly, each pup was decapitated and the cortex was digested in 0.5 mg/mL papain at 37 °C for 15 min. The tissue was dissociated in Hibernate A medium (containing B27 supplement) by aspirating trituration. The cells were plated (5×10^4 cells/cm²) onto poly-D-lysine-coated dishes and maintained in Neurobasal medium containing the B27 supplement, 10 units/mL penicillin, 10 mg/mL streptomycin, and 0.5 mg/mL glutamine (5 % CO₂/9 % O₂) for 3 days. The cells were then exposed to cytosine-β-D-arabinofuranoside (5 μM) for 1 day to inhibit the proliferation of non-neuronal cells. The cells were used for the experiment on the fifth day. The optimized concentration (10 μM) and treatment duration (40 h), of A β _{25–35} were determined previously.²³ Cortical neurons were treated with various concentration of compounds **1–15** or vehicle (0.01 % DMSO), to determine the toxic effect of these compounds. Only compound **10** showed toxic effect on cortical neurons at 50 μM. Subsequently, cortical neurons were pretreated with 10, 20, and 50 μM of compounds (with the exception of compound **10** which was 5, 10, and 20 μM) for 2 h and then exposed to 10 μM of A β _{25–35} for 40 h. Neurotoxicity was measured by MTT reduction assay.

S 100 Neurotoxicity Assay

MTT reduction was used to evaluate the neurotoxicity. The cells were incubated with minimum essential medium containing 0.5 mg/mL MTT for 1 h. The medium was aspirated, and the formazan particles were dissolved with lysis buffer (10 % sodium dodecyl sulfate, 3.3 mM HCl, 50 % dimethylformamide). The absorbance at 600 nm was measured using an enzyme-linked immunosorbent assay reader.

Statistical Analysis. All experiments were performed at least three times, and the results are expressed as the means ± SEM. The statistical analyses were based on the Student's *t* test or the Mann-Whitney *U* test, and all calculations were performed with SigmaPlot (Systat Software, San Jose, CA). A *p* value < 0.05 was considered statistically significant.

S 101 Compound **2** prevented cell death of cortical neurons induced by A β -(25–35).



Cortical neurons were pretreated with vehicle (V) or 50 μ M of compounds (except that for **10**, is 20 μ M) for 2 h and then exposed to 10 μ M of A β -(25–35) for 40 h. Cell viability was measured by MTT reduction assay. Results are means \pm SEM. from four independent experiments and expressed relative to control (C). Significant differences between cells treated with A β -(25–35) plus vehicle (V) and A β -(25–35) plus compounds are indicated by ***, $p < 0.001$. The neurotoxicity % = 100 % – MTT reduction %.